MEETINGS - Investment in Innovation (Belgium) September 2005:
This article was originally published in Clinica
Medtech Insight will host In3: Investment in Innovation, a preview of early-stage medical technology companies, through two events. One at the Crowne Plaza in Brussels, Belgium on September 20-21 2005 and the other at The Westin Copley Place in Boston, Massachusetts on October 10-11. For further information on both events, visit: http://www.medtechinsight.com/conferences.html
You may also be interested in...
Officials from the US Food and Drug Administration cited their reasons for refusing to review new applications for companies with unresolved data integrity failures.
However, Vaccinex sees possible efficacy for SEMA4D inhibition in later-stage Huntington’s as well as Alzheimer’s disease. Pepinemab is also being studied with Keytruda in head-and-neck cancer.
In last year’s acquisition, Bristol Myers Squibb agreed to pay Celgene investors another $9 per share based on three approvals, including idecabtagene vicleucel (bb2121) by 30 March 2021.